Trial Profile

A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Taselisib (Primary) ; Enzalutamide
Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

03 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Jul 2022.
05 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
27 Apr 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com